Hospital
Ochsner Medical Center - Northshore, L.L.C.
Ochsner Medical Center - Northshore, L.L.C. was paid $6.70M by Medicaid between Jan 2018 and Jun 2023, across 75 billing codes. Its largest line is 99284, emergency room visit (serious) — 34% of everything it billed.
33Billing provider infoOCHSNER MEDICAL CENTER - NORTHSHORE, L.L.C.
SLIDELL, LA 70461
SLIDELL, LA 70461
33aNPI1043533706assigned 03/10/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$6.70M
24GClaims172,781
24DCodes billed75
24AFirst – last monthJan 2018 – Jun 2023
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#41 of 96
Median peer was paid$5.17M
This provider vs. median1.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 19,849 | $780K | |
| 2019 | 24,152 | $940K | |
| 2020 | 18,500 | $670K | |
| 2021 | 35,699 | $1.45M | |
| 2022 | 50,753 | $1.99M | |
| 2023 | 23,828 | $873K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 34% | 21,251 | 19,138 | $2.29M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 20% | 18,070 | 16,549 | $1.36M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 8,018 | 7,107 | $1.33M |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 4.1% | 6,833 | 6,112 | $278K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.4% | 4,120 | 3,667 | $228K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 2.2% | 759 | 351 | $151K |
| 80053 | Comprehensive metabolic panel | 1.8% | 16,837 | 14,300 | $121K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.8% | 3,808 | 3,192 | $119K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 19,325 | 16,225 | $99K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.4% | 4,085 | 3,590 | $92K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 2,991 | 751 | $73K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,236 | 1,123 | $65K |
63 more codes
| 11043 | <1% | 442 | $59K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 23,784 | $47K |
| 81025 | <1% | 7,247 | $45K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,249 | $36K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,419 | $34K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,699 | $33K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 87 | $27K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,370 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 297 | $21K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,573 | $17K |
| 86803 | <1% | 1,741 | $16K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,056 | $13K |
| 87634 | <1% | 215 | $12K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 93 | $10K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 360 | $10K |
| 81000 | <1% | 3,208 | $9K | |
| 87400 | <1% | 832 | $7K | |
| 83690 | <1% | 1,452 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 572 | $6K |
| G0378 | Hospital observation service, per hour | <1% | 69 | $6K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 253 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 941 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 17 | $5K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 106 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 146 | $5K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 451 | $4K |
| 80061 | Lipid panel | <1% | 462 | $4K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,964 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 20 | $4K |
| 76830 | Ultrasound, transvaginal | <1% | 27 | $3K |
| 81003 | <1% | 1,459 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 27 | $2K |
| 84484 | <1% | 239 | $2K | |
| 97161 | <1% | 39 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12 | $1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 12 | $1K |
| 86804 | <1% | 80 | $1K | |
| 87807 | <1% | 101 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 49 | $970.76 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 84 | $662.65 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 1,741 | $463.86 |
| 94761 | <1% | 73 | $414.15 | |
| 83735 | <1% | 138 | $399.81 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 29 | $361.31 |
| 83880 | <1% | 13 | $357.67 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 14 | $291.40 |
| 87081 | <1% | 39 | $271.94 | |
| 84439 | <1% | 43 | $251.72 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 546 | $210.97 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 250 | $178.93 |
| 97602 | <1% | 20 | $148.98 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14 | $89.96 |
| 82962 | <1% | 30 | $76.62 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 30 | $67.21 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 14 | $28.42 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 14 | $13.73 |
| J3490 | Unclassified drugs | <1% | 438 | $1.05 |
| J2704 | Injection, propofol, 10 mg | 0% | 426 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 250 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 29 | $0.00 |
| 00813 | 0% | 14 | $0.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPOSECAI, SCOTT (EVP-CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| East Baton Rouge Medical Center LLC | Baton Rouge, LA | $48.28M |
| Ochsner Clinic LLC | New Orleans, LA | $73K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.